• LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19 vaccine.
  • Depending on study recruitment rate, Invivyd expects to report topline data from LIBERTY in Q3 2026, to accompany anticipated data from the pivotal DECLARATION clinical trial.
  • Prior exploration of monoclonal antibody (mAb) interaction with vaccine published here suggests a minimal clinical consequence to a similar interaction today, but could provide data to aid in potential product labelling language, if approved. This earlier work demonstrated an expected, modest reduction in vaccine-induced neutralizing antibody titers from co-administration of mAb and vaccine, in seronegative populations, with T Cell and other vaccine-induced metrics minimally changed.
  • LIBERTY is part of Invivyd's broader REVOLUTION clinical program, including DECLARATION, designed to characterize the profile of mAb-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable Americans